The Journal of Urology
Volume 183, Issue 2 , Pages 743-751 , February 2010

The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic Effect on Renal Cell Carcinoma

  • Tsz-fung F. Chow

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Marina Mankaruos

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Andreas Scorilas

      Affiliations

    • Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Panepistimiopolis, Athens, Greece
    • ,
  • Youssef Youssef

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Andrew Girgis

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Sarah Mossad

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Shereen Metias

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • Yostina Rofael

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • ,
  • R. John Honey

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with Cook and Pleuromed.
    • ,
  • Robert Stewart

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
    • ,
  • Kenneth T. Pace

      Affiliations

    • Division of Urology, Department of Surgery, St. Michael's Hospital, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with Sanofi-Synthelabo.
    • ,
  • George M. Yousef

      Affiliations

    • Department of Laboratory Medicine and Keenan Research Centre, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada
    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationCorrespondence and requests for reprints: Department of Laboratory Medicine, St. Michael's Hospital, 30 Bond St., Toronto, Ontario, M5B 1W8, Canada (telephone: 416-864-6060, extension 6129; FAX: 416-864-5648)

Received 29 April 2009

References 

  1. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828
  2. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65:9628
  3. Zanette DL, Rivadavia F, Molfetta GA, et al. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res. 2007;40:1435
  4. Takakura S, Mitsutake N, Nakashima M, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008;99:1147
  5. Monzo M, Navarro A, Bandres E, et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 2008;18:823
  6. Nagel S, Venturini L, Przybylski GK, et al. Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2009;50:101
  7. Aguda BD, Kim Y, Piper-Hunter MG, et al. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A. 2008;105:19678
  8. Xu X, Hong Y, Kong C, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92. FEBS Lett. 2008;582:2850
  9. Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008;68:5540
  10. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282:2135
  11. Chow T, Youssef Y, Lianidou E et al: Differential expression profiling of microRNAs in renal cell carcinoma and their clinical implications. Unpublished data.
  12. Romaschin AD, Youssef Y, Chow TF, et al. Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem. 2009;390:125
  13. Siu KWM, Desouza L, Scorilas A et al: Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. Unpublished data.
  14. Jung M, Mollenkopf HJ, Grimm C, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009;Epub ahead of print
  15. Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008;216:418
  16. Inomata M, Tagawa H, Guo YM, et al. MicroRNA-17-92 downregulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2008;113:396
  17. Yu J, Wang F, Yang GH, et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun. 2006;349:59
  18. Zhang Y, Zhang R, Su B. Diversity and evolution of MicroRNA gene clusters. Sci China C Life Sci. 2009;52:261
  19. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008;173:856
  20. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 2006;25:6202
  21. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?. Cancer Gene Ther. 2008;15:341
  22. Yamakawa K, Morita R, Takahashi E, et al. A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res. 1991;51:4707
  23. Chow TF, Crow M, Earle T, et al. Kallikreins as microRNA targets: an in silico and experimental-based analysis. Biol Chem. 2008;389:731
  24. Yousef GM. MicroRNAs: a new frontier in kallikrein research. Biol Chem. 2008;389:689
  25. Schaefer A, Jung M, Kristiansen G, et al. MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol. 2008;Epub ahead of print
  26. Matsubara H, Takeuchi T, Nishikawa E, et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene. 2007;26:6099
  27. Cloonan N, Brown MK, Steptoe AL, et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol. 2008;9:R127
  28. Wang Q, Li YC, Wang J, et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci U S A. 2008;105:2889
  29. Dutta KK, Zhong Y, Liu YT, et al. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 2007;98:1845
  30. Horikawa Y, Wood CG, Yang H, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res. 2008;14:7956

 Study received approval from the research ethics board, St. Michael's Hospital, Toronto, Canada.

 Supported by Canadian Institute of Health Research Grant 86490.

 Supplementary material for this article can be obtained at http://www.stmichaelshospital.com/pdf/labs/suppl-fig-1.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-fig-2.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-1.pdf, http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-2.pdf and http://www.stmichaelshospital.com/pdf/labs/suppl-tbl-3.pdf.

PII: S0022-5347(09)02627-5

doi: 10.1016/j.juro.2009.09.086

The Journal of Urology
Volume 183, Issue 2 , Pages 743-751 , February 2010

Article Tools

* Image Usage & Resolution